Federal RuleAug 21
62
DOL Rewrites Disability Rules for 'Merit-Based Opportunity' Push
RuleLabor DepartmentFederal Contract Compliance Programs OfficeSignificant Wallet
119-hr-1796119th CongressWALLET
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
Sponsored By: Representative James, John [R-MI-10]
Introduced
Summary
Would reauthorize and expand the federal sickle cell demonstration program and boost its funding. The bill would add explicit support for treating sickle cell disease and preventing and treating its complications, and it expresses a call for more research on heritable blood disorders.
Show full summary
- Families and patients: People with sickle cell disease would get clearer federal support for both disease care and for preventing and treating complications. This targets better care and follow up for affected children and adults.
- Researchers and providers: The program would allow grants, contracts, or cooperative agreements, so academic centers and health systems could receive federal grants or contracts to run projects.
- Public health and state programs: Authorized funding rises to $8.2 million per year for 2025–2029, up from $4.5 million in the prior authorization, enabling expanded surveillance, prevention, and treatment activities.
*Would authorize higher annual funding for the program — $8.2 million per year for 2025–2029 versus $4.5 million previously — increasing federal program outlays relative to the prior authorization.*
Personalized for You
How does this bill affect your finances?
Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
More funding for sickle cell care
If enacted, this would boost federal support for the sickle cell demonstration program to about $8.205 million each year for 2025–2029, up from $4.455 million in 2019–2023. The program could award grants and cooperative agreements, not just contracts. It would also focus on treating sickle cell disease and preventing and treating its complications. People living with sickle cell and their caregivers could see more services and support through participating clinics and groups.
Sponsors & CoSponsors
Sponsor
James, John [R-MI-10]
MI • R
Cosponsors
Rep. Veasey, Marc A. [D-TX-33]
TX • D
Sponsored 3/3/2025
Rep. Carter, Troy A. [D-LA-2]
LA • D
Sponsored 3/3/2025
Rep. Davis, Danny K. [D-IL-7]
IL • D
Sponsored 3/3/2025
Rep. Kiggans, Jennifer A. [R-VA-2]
VA • R
Sponsored 3/3/2025
Rep. Vindman, Eugene Simon [D-VA-7]
VA • D
Sponsored 8/15/2025
Rep. Bishop, Sanford D. [D-GA-2]
GA • D
Sponsored 1/16/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov